AptarGroup’s nasal unidose system to deliver neffy alllergy treatments

AptarGroup’s Unidose Liquid System is the delivery system approved with neffy – epinephrine nasal spray -, the first and only needle-free treatment approved by the FDA for the emergency treatment of patients with allergic reactions Type I, including anaphylaxis. This marks the first regulatory approval worldwide for nasally-delivered epinephrine. Aptar’s Unidose is a single-use, ready-to-use, one-step nasal delivery system used to administer neffy to a patient during a severe allergic reaction. During such an event, the patient, healthcare professional, caregiver or user presses a small plunger on the bottom of the nasal spray system to release the drug in a single spray into the nostril. This novel treatment for severe allergic reaction is an example of a Combination Product submission, and benefited from Aptar Pharma’s Services offering, a comprehensive portfolio of stage-specific development packages.